IPOSchedule
EN
EnglishDeutschFrançais
2026 offering

Regenlab USA IPO

RegenLab develops and commercializes regenerative medicine biologics and tissue-engineering platforms.

  • RGNA
  • Nasdaq
  • United States
  • Healthcare
Filed 25 Sept 2026

Offering in progress. A listing date has not been announced, and proposed terms may change.

Last verified 3 Oct 2026

Company overview

Regenlab USA website

The company offers outpatient-compatible biologics, including platelet-rich plasma, platelet-rich plasma combined with hyaluronic acid, bone marrow-derived products, crosslinked scaffolds and fibrin-based matrices. These offerings serve musculoskeletal regeneration, advanced wound care, medical aesthetics and women’s health.

Company country
United States

Offering details

USD · Base offering, before overallotment

Exchange
Nasdaq
Ticker
RGNA

IPO timeline

  1. Registration filed

Filings and documents

Other IPO profiles

Industrials01

VME Companies

VME Companies provides engineering, procurement and construction services and modular process systems and equipment.

IPO valuation$276M – $345M
Filings Nasdaq Capital MarketIPO
Industrials02

Helio Corp /FL/

Helio Corporation is a holding company providing technology, engineering, and research and development services.

Listing valuation$29.5M – $36.8M
Filings Nasdaq Capital MarketUplisting
Healthcare03

Neuro Spectrum Insights

Neuro Spectrum Insights develops software to support autism diagnosis through MRI image analysis.

IPO valuation$60.4M – $75.4M
Filings NYSE AmericanIPO